Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid (Q21261395)

19 August 2022

Paulo G Plaggert

2

Paulo G

Plaggert

1 reference

19 August 2022

Maria Bernadete D Resende

3

Maria Bernadete D

Resende

1 reference

19 August 2022

Edmar Zanoteli

4

Edmar

Zanoteli

1 reference

19 August 2022

Umbertina C Reed

5

Umbertina C

Reed

1 reference

SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy

19 August 2022

language of work or name

English

0 references

publication date

2011

0 references

published in

BMC Neurology

0 references

volume

11

0 references

issue

1

0 references

page(s)

36

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number.

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Phase II open label study of valproic acid in spinal muscular atrophy

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Identification and characterization of a spinal muscular atrophy-determining gene

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Spinal muscular atrophy: from animal model to clinical trial.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Carnitine in the treatment of valproic acid-induced toxicity

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Two cases of valproic acid poisoning treated with L-carnitine.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Perspectives on clinical trials in spinal muscular atrophy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Natural history of denervation in SMA: relation to age, SMN2 copy number, and function

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Epidemiological data on Werdnig-Hoffmann disease in Germany (West-Thüringen).

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

The role of histone acetylation in SMN gene expression.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Valproic acid increases SMN levels in spinal muscular atrophy patient cells.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Epidemiology of Spinal Muscular Atrophies in a Sample of the Italian Population

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2.

30 May 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2377-11-36

Valproic acid treatment in six patients with spinal muscular atrophy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2377-11-36

Serum and muscle carnitine levels in epileptic children receiving sodium valproate

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2377-11-36

Disability evaluation: Barthel's index

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078847

Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy

29 November 2018

1 reference

12 December 2020

A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients

1 reference

12 December 2020

In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate

1 reference

12 December 2020

Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-11-36

0 references